Comparison of Multiple Clinical Testing Modalities for Assessment of NPM1-Mutant AMLAmanda Lopez, Michael Kluk, Sanjay S. Patel et al.|Frontiers in Oncology|2021Cited by 19
CPX-351 As First Intensive Therapy for Elderly Patients with AMLEllen K. Ritchie, Gail J. Roboz, Sumaiya Miah et al.|Blood|2019Cited by 6
Comparison of Patients with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated with Venetoclax and Hypomethylating Agents Vs Other Therapies By <i>TP53</i> and <i>IDH1/2</i> Mutation: Results from the AML Real World Evidence (ARC) InitiativeOfir Wolach, Aaron D. Goldberg, Tsila Zuckerman et al.|Blood|2022Cited by 2
Phase II Clinical Study of the Clinical Efficacy and Safety of Tosedostat in Patients with Myelodysplastic Syndromes (MDS) after Failure of Hypomethylating Agent-Based TherapySangmin Lee, Gail J. Roboz, Pinkal Desai et al.|Blood|2017Cited by 1
Effect of Cord Blood Vs Adult Stem Cell Sources on Outcome of Patients with Mutated TP53 Hematologic MalignanciesAlexandra Gomez-Arteaga, Koen van Besien, Jingmei Hsu et al.|Transplantation and Cellular Therapy|2021Cited by 0